| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 2161382 | Radiotherapy and Oncology | 2006 | 6 Pages |
Abstract
Further use of PLI may be limited due to asymptomatic, but detectable biochemical changes of liver function when PLI is sequentially combined with chemotherapy. HART, on the other hand, provides acceptable rate of local control, and is well tolerated, also when combined with postoperative chemotherapy.
Related Topics
Life Sciences
Biochemistry, Genetics and Molecular Biology
Cancer Research
Authors
Rafal Suwinski, Jerzy Wydmanski, Iwona PaweÅczyk, Jacek Starzewski,